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Abstract
Background: The role of TNF-α in affecting the fate of tumors is controversial, while some
studies have reported apoptotic or necrotic effects of TNF-α, others provide evidence that
endogenous TNF-α promotes growth and development of tumors. Understanding the
mechanism(s) of TNF-α mediated growth arrest will be important in unraveling the contribution
of tissue associated macrophages in tumor resistance. The aim of this study was to investigate the
role of Cyclin Dependent Kinase Inhibitors (CDKI) – p21cip/waf1 and p27kip1 in TNF-α mediated
responses in context with p53 and activation of NF-κB and Akt pathways. The study was done with
human glioma cell lines -LN-18 and LN-229 cells, using monolayer cultures and Multicellular
Spheroids (MCS) as in vitro models.
Results: TNF-α induced inhibition of proliferation and enhanced the expression of p21cip/waf1 and
p27kip1 in LN-18 cells. p21 was induced on exposure to TNF-α, localized exclusively in the nucleus
and functioned as an inhibitor of cell cycle but not as an antiapoptotic protein. In contrast, p27 was
constitutively expressed, localized predominantly in the cytoplasm and was not involved in arrest
of proliferation. Our data using IκBα mutant LN-18 cells and PI3K/Akt inhibitor-LY294002 revealed
that the expression of p21 is regulated by NF-κB. Loss of IκBα function in LN-229 cells (p53
positive) did not influence TNF-α induced accumulation of pp53 (Ser-20 p53) suggesting that p53
was not down stream of NF-κB. Spheroidogenesis enhanced p27 expression and p21 induced by
TNF-α was significantly increased in the MCS compared to monolayers.
Conclusion: This study demarcates the functional roles for CDKIs-p21cip/waf1 and p27kip1 during
TNF-α stimulated responses in LN-18 glioma cells. Our findings provide evidence that TNF-α-
induced p21 might be regulated by NF-κB or p53 independently. p21 functions as an inhibitor of
cell proliferation and does not have a direct role in rendering the cells resistant to TNF-α mediated
cytotoxicity.
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Gliomas are the most common malignant brain tumors in
adults [1]. The median survival of the patients is less than
two years and the prognosis remains poor despite exten-
sive research and advances in radiation therapy and chem-
otherapeutic regimes. The factors responsible for the
aggressive behavior of gliomas include marked local inva-
sive growth, neovascularization and evasion to immune
responses [2]. Macrophages comprise an important com-
ponent of the immune system against tumors. In gliomas,
macrophages are recruited and remain at the site of tumor
constituting a major proportion of the tumor mass [3].
The ability of gliomas to escape the host immune system
is thought to contribute to the malignant behavior of
these tumors, raising speculation about the role of these
tumor infiltrating macrophages in progression and aggres-
siveness of gliomas [3]. Secretion of cytokines, particularly
TNF-α, by activated macrophages is known to affect sur-
vival, growth and proliferation of the tumor [4]. TNF-α
mediates apoptotic or necrotic effects in many tumors
depending on cell types, and causes growth inhibition in
40% of tumor cell lines [5-7]. Reports on the effects of
TNF-α on glioma growth and progression are contradic-
tory. TNF-α-induced responses range from cytotoxicity to
cytostatic effects [8-10]. Earlier in vivo studies with tumors
indicated that TNF-α was a death inducer and hence used
in clinical trials for treatment of cancers [11]. However
recent reports provide evidence that endogenous TNF-α
promotes growth and development of tumors [12,13]. In
gliomas, TNF-α is shown to reduce growth and prolong
survival by enhancing macrophage recruitment and
microcyst formation [14]. Understanding the mecha-
nism(s) of TNF-α mediated growth arrest will be impor-
tant in unraveling the contribution of tissue associated
macrophages in tumor resistance in gliomas.
The progression of cells through cell cycle depends on the
activation of cyclins and cyclin dependent kinases – CDKs
which function together in the G1 phase for initiating S
and progression to G2/M phases. The activity of the com-
plexes is regulated by two families of cyclin dependent
kinase inhibitors (CDKIs)-including INK4 proteins that
bind only to CDK4/CDK6 and are specific for G1 phase
and the cip/kip proteins which include p21cip/waf1 and p27
kip1 and are not specific for any particular cell cycle phase
[15,16]. p21 is an universal inhibitor of cell cycle progres-
sion and arrests in G1 as well as G2 phases [17]. p21 neg-
atively regulates cell cycle progression by inhibiting CDK2
and CDK4 and blocks DNA replication by binding to
PCNA [18]. p21 is also implicated in terminal differentia-
tion, replicative senescence and protection from p53
dependent and p53-independent apoptosis [19,20]. p27
arrests at G1 phase of the cell cycle by contact inhibition
and controls the G1/S transition by inhibiting the activity
of a wide variety of cyclin/CDK complexes [21]. It is
expressed in many tumors and may be partly responsible
for growth arrest in tumor cells [22,23]. Though muta-
tions in p27 are rare, a negative correlation between p27
expression and tumor progression is documented in
many cancers and loss of p27 in tumors is associated with
poor prognosis [24].
Elucidation of cellular and molecular mechanisms
involved in survival/death signaling in response to chem-
otherapeutic agents has been a focus of recent studies for
understanding drug resistance in tumors. However, such
studies have been hampered by limitations in the conven-
tional in vitro models as they do not reflect the complexi-
ties of solid tumors. Multicellular spheroids (MCS)
closely resemble the in vivo situation with regard to cell
shape and environment, which in turn can affect the gene
expression and behavior of the cells [25]. The biological
significance and clinical relevance of MCS have been well
documented and these experimental systems have been
used for studying micro-environmental effects on basic
mechanisms, such as regulation of proliferation, metabo-
lism, differentiation, cell death, invasion, angiogenesis
and immune response [26-28]. Though the MCS show
greater resistance compared to the two dimensional-mon-
olayer cultures, the mechanisms that confer greater resist-
ance to radiotherapy, chemotherapy in the MCS are not
well understood [29]. In this study, we analyzed the effect
of TNF-α on proliferation and survival of human glioma
cells and investigated the role of CDKIs-p21cip/waf1 and
p27kip1 in context with p53 and activation of NF-κB and
Akt pathways using monolayer cultures and MCS as in
vitro models.
Results
TNF-α-induced inhibition of proliferation is mediated by 
TNFR1
Initial experiments were done to assess the effect of TNF-
α on cell growth in LN-18 cells. Monolayers and sphe-
roids derived from LN-18 cells were treated with TNF-α
and cell proliferation was measured by tritiated thymidine
incorporation assay. TNF-α (2.5–100 ng/ml) induced
inhibition of proliferation (25%) even at the lowest con-
centration, with at least two fold greater inhibition (65%)
in spheroids at concentrations ≥10 ng/ml (Fig. 1A). TNF-
α-induced signaling are mediated via distinct cell surface
receptors, TNFR1 (~55 kDa) and TNFR2 (~75 kDa) [30].
The expression of these receptors in LN-18 cells was stud-
ied by RT-PCR and flowcytometry analysis. The RT-PCR
data and the histoplots show that LN-18 cells express high
levels of TNFR1 compared to TNFR2. This was in contrast
with another human glioma cell line-U87MG, which
showed high expression of both the receptors (Fig. 1B and
1C). To investigate the receptor mediated signaling, cells
were pre-incubated with neutralizing antibodies to
TNFR1 and TNFR2 (50 µg/ml) and subsequently treatedPage 2 of 12
(page number not for citation purposes)
Molecular Cancer 2007, 6:42 http://www.molecular-cancer.com/content/6/1/42with TNF-α for 24 hr. Pretreatment with neutralizing anti-
bodies to TNFR1 but not TNFR2 reversed the inhibition
significantly (Fig. 1D), suggesting that TNF-α stimulated
responses were mediated by TNFR1. TNFR1 agonistic anti-
body (1–50 µg/ml) induced inhibition of proliferation up
to 50% at concentrations ≥10 µg/ml in the MCS, while the
inhibition was only 15% in the monolayers (Fig. 1E). As
the inhibition with TNF-α and TNFR1 agonistic antibody
was significantly higher in the spheroids, we determined
the levels of TNFR1 in the two culture models by Western
blotting and found that the expression of TNFR1 was
many fold higher in the spheroids (Fig. 1F). These experi-
ments demonstrated that TNF-α-induced inhibition of
proliferation was significantly higher in spheroids com-
pared to monolayers in LN-18 cells and the effect was
mediated by TNFR1.
TNF-α up regulates p21 and p27 expression
The inhibition in cell growth induced by TNF-α was stud-
ied by cell cycle analysis. LN-18 cells were treated with
TNF-α up to 72 hr period and analyzed for DNA content
by flow-cytometry at 24 hr intervals. Spheroids cultured
for 24 hr had higher population of G0/G1 cells compared
to the corresponding monolayer. TNF-α treatment signif-
icantly increased the cell population in G0/G1 cells in
both the models at all the time points but to a greater
extent in spheroids compared to monolayer (Fig. 2A)
Cyclin dependent kinase inhibitors (CDKI) p21cip/waf1 and
p27 kip1 are important in TNF-α mediated signaling [31].
We studied the effect of TNF-α on the expression of these
CDKI proteins in the two culture models of LN-18 cells by
immunoblotting. As shown in Figure 2B, the expression
of p21 was below the level of detection in the both the cul-
ture systems. On stimulation with TNF-α, the level in
monolayers was marginally increased while the expres-
sion was strongly enhanced in the spheroids. Our data
also revealed that LN-18 cells constitutively expressed p27
and the levels increased drastically with spheroidogenesis.
Stimulation with TNF-α resulted in further upregulation
of p27 expression in both the models (Fig. 2B). We further
performed time course experiments by Confocal Laser
scanning Microscopy (CLSM) to study the expression and
localization of p21 and p27 in response to TNF-α. We
found that p21 was not detectable in the control cells con-
firming the data from immunoblotting experiments. p21
was induced from 3 hr post-treatment with TNF-α with
further increase in the number of p21 positive cells at 6 hr.
The level decreased at 12 hr and complete loss of expres-
sion was observed at 24 hr. Using an antibody that recog-
nizes p21 in the nucleus as well as cytoplasm it was found
that p21 was restricted to the nucleus (Fig. 2C). The cells
were highly positive for p27 (>95%) with predominantly
cytoplasmic staining though nuclear staining was also
seen in some cells. TNF-α treatment marginally enhanced
the p27 expression from 3 hr onwards (Fig. 2C).
TNF-α-induced p21 is regulated by NF-κB and p53 
independently
NF-κB pathway is a one of the major mediators in TNF-α
induced effects. As our preliminary experiments indicated
that p21 was induced on stimulation with TNF-α in LN-
18 cells, we examined the role of NF-κB pathway in the
regulation of p21 using a stable IκBα mutant LN-18 cell
line. Characterization of the IκBα mutant cell line con-
firmed that the cells were sensitive to TNF-α mediated cell
death. Figure 3A and 3B shows the response of the IκBα
mutant cell line to TNF-α determined by MTT assay and
PARP cleavage. Western blotting and immunofluores-
cence analysis revealed that p21 was not detected in the
IκBα mutant LN-18 cells and was not induced on stimu-
lation with TNF-α (Fig. 3C, and 3D) suggesting that p21
expression might be regulated by the NF-κB pathway. On
the other hand, the expression of p27 was not altered in
IκBα mutant LN-18 cells (Fig. 3D and Fig. 2B), implying
that p27 expression was not under the control of NF-κB.
p21 is regulated mainly via tumor suppressor protein-
p53. Recently, p52/p100 NF-κB was described to regulate
p53 function and hence influence the p53-regulated deci-
sion-making following DNA damage, a process involving
p21 [32]. As LN-18 cells express mutant p53 protein, to
examine if NF-κB influenced the p21 expression directly
or whether it was via p53, experiments were performed
using LN-229, a human glioma cell line expressing wild-
type p53 [33]. Cells were exposed to TNF-α for 6 hr and
analyzed for the expression of phosphorylated ser20-p53
(pp53) and p21. Stimulation with TNF-α led to enhanced
accumulation of phosphorylated p53 in the nucleus,
interestingly, the untreated control cells also displayed
detectable levels of pp53. In contrast, the expression of
nuclear p21 decreased in TNF-α treated cells compared to
controls (Fig. 4A). To delineate the pathways regulating
p21, the effect of TNF-α on pp53 and p21 was studied in
LN-229 cells transfected with IκBα dominant negative
construct. The loss of IκBα activity in the transfected cells
was evident by the inhibition of p65 translocation to
nucleus on stimulation with TNF-α compared with
untransfected LN-229 cells (Fig. 4B). To address the ques-
tion whether loss of NF-κB activation in these cells might
influence the levels of pp53 and p21, transfected cells
exposed to TNF-α for 6 hr were stained with antibodies to
Ser20-p53 and p21. As shown in figure 5, there was no sig-
nificant difference in the accumulation of pp53 or nuclear
p21 between the transfected and untransfected cells.
These findings led us to conclude that p53 might not func-
tion downstream of NF-κB and secondly, TNF-α-induced
p21 can be regulated by p53 and NF-κB independently.Page 3 of 12
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A-F. TNF-α-induced inhibition of proliferation in LN-18 cells is mediated by TNFR1Figure 1
A-F. TNF-α-induced inhibition of proliferation in LN-18 cells is mediated by TNFR1. (A) LN-18 cells cultured as 
monolayers and spheroids for 24 hr were treated with serial concentrations of TNF-α for 24 hr, during the last 18 hr of treat-
ment, 1 µCi of triatiated thymidine was added to the wells. The cells were harvested and the radio activity-counts per minute 
(CPM) was measured and percent inhibition of proliferation was calculated considering the CPM in untreated cells as 100%. B) 
Expression of TNFR1 and TNFR2 was analyzed by RT-PCR in LN-18 cells and compared with human glioma cell line-U87MG, 
used as positive control. β-actin was used as control. C) Expression of TNFR1 and TNFR2 in LN-18 cells and U87MG cells ana-
lyzed by flowcytometry, bold lines represent TNFR1/TNFR2 expression and dotted lines depict profiles with isocontrol anti-
body. D) Monolayers and spheroids were preincubated with neutralizing antibodies to TNFR1 and TNFR2 (50 µg/ml) or 
isocontrol antibody for 2 hr and treated with TNF-α (10 ng/ml) for 24 hr and proliferation assay was done as described above. 
E) Monolayers and spheroids were treated with serial concentrations of TNFR1 agonistic antibody or isocontrol antibody for 
24 hr and proliferation was determined by triatiated thymidine incorporation assay. The data for A, D and E is the mean ± SE 
of at least three independent experiments done in triplicates. * p < 0.05-comparison of inhibition of proliferation in TNF-α 
treated cells in the presence and absence of TNFR neutralizing antibodies for D and between treated and controls cells for A 
and E. F) Levels of TNFR1 expression by Western blotting in monolayers (M) and spheroids (S) cultured for 24 hr. The blots 
were stripped and reprobed with β-actin, which served as a loading control of proteins.
Molecular Cancer 2007, 6:42 http://www.molecular-cancer.com/content/6/1/42p21 siRNA did not induce cell death in LN-18 cell line
Though the role of p21 in cell cycle regulation and growth
is well established [19], recently, p21 was reported to also
have anti-apoptotic function [34]. The observations that
(1) TNF-α induced p21 expression in LN-18 parental cells
but not in IκBα mutant cells and (2) IκBα mutant cells
were sensitive while the parental cells were resistant to
TNF-α mediated cell death prompted us to examine
whether p21 functioned as anti-apoptotic molecule in the
LN-18 parental cells. For this purpose, cells transfected
with p21 siRNA (100 nM) oligonucleotides were treated
with TNF-α (10 ng/ml) for 24 hr. The effectiveness of
transfection with p21 siRNA was confirmed by determin-
ing the expression of p21 by Confocal Laser Scanning
Microscopy in transfected cells (Fig. 6A). Results from
MTT assay revealed no difference in the viability between
the untransfected and transfected cells treated with TNF-α,
indicating that p21 did not have a protective role in resist-
ance to TNF-α induced cell death in LN-18 cells (Fig. 6B).
The results were confirmed by trypan blue dye exclusion
method (data not shown). p21 has to be translocated to
cytoplasm and phosphorylated to function as an antiap-
optotic protein. In our experiments, as mentioned earlier,
p21 was localized exclusively in the nucleus suggesting
that p21 was not phosphorylated (Fig. 2C). This observa-
tion was confirmed using a phospho-specific p21 anti-
body (data not shown). These observations suggest that
TNF-α-induced p21 in LN-18 cells does not function as an
antiapoptotic protein.
p21 but not p27 was involved in the inhibition of 
proliferation
Further work was done to investigate the role of p21 and
p27 in the inhibition of proliferation induced by TNF-α.
To this end, cells were transfected with p21 siRNA oligo-
nucleotides and treated with TNF-α (10 ng/ml) and pro-
liferation was assessed by tritiated thymidine
incorporation assay. The inhibition was reversed signifi-
cantly by p21 siRNA oligonucleotides indicating that p21
was involved in arresting the proliferation induced by
A-B. TNF-α induced arrest of cells in G0/G1 phase and enhanced expression of p21 and p27Figure 2
A-B. TNF-α induced arrest of cells in G0/G1 phase and enhanced expression of p21 and p27. A) Monolayers and 
spheroids were treated with TNF-α (10 ng/ml) for 24, 48, and 72 hr and cell cycle analysis was done by flowcytometry. The 
percent population of cells in G0/G1, S and G2/M phases of cell cycle was determined using Modfit software. The plot is a rep-
resentative of three similar experiments. B) Monolayers (M) and spheroids(S) were treated with TNF-α (10 ng/ml) for 3 hr and 
the expression of p21 and p27 was determined by Western blotting. Blots were reprobed for β-actin and used as control for 
equal loading of proteins. C. Differential expression and localization of p21 and p27 in LN-18 cells stimulated with 
TNF-α. LN-18 cells were grown on coverslips for 24 hr and treated with TNF-α (10 ng/ml) for different time periods. Cells 
were stained with antibody recognizing nuclear and cytoplasmic p21, or with p27 antibody followed by secondary antibody 
labeled with Cy3. The expression of p21/p27 is depicted as red fluorescence. DAPI was used for nuclear staining (blue). The 
merged images show nuclear localization of p21 and p27 localized predominantly in the cytoplasm. (Magnification 63×).Page 5 of 12
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cells transfected with p27 antisense oligonucleotides (200
nM) revealed no difference in the inhibition between con-
trols and transfected cells treated with TNF-α (Fig. 7B).
Together, these results show that p21 did not function as
an antiapoptotic protein and secondly p21 but not p27
played a crucial role in the arrest of proliferation induced
by TNF-α.
The CDKIs, p21 and p27 are reported to be also regulated
by PI3K/Akt pathway [35-38], we therefore examined the
role of PI3K/Akt pathway by treating LN-18 cells sensi-
tized with LY294002, a pharmacological inhibitor of
PI3K/Akt pathway with TNF-α. The inhibitor had no effect
on the fluorescence intensity or the percent positivity of
p21 or p27 positive cells in TNF-α stimulated cells, sug-
gesting that PI3K/Akt pathway was not involved in regula-
tion of these CDKIs in LN-18 cells (Fig. 8A and 8B).
Discussion
In this report, we established that though p21cip/waf1 and
p27kip1 are upregulated in response to TNF-α, p21 but not
p27 is involved in the arrest of proliferation in TNF-α
stimulated LN-18 glioma cells. TNF-α-induced inhibition
of proliferation was mediated via TNFR1. This observa-
tion is significant as most aggressive gliomas express high
levels of TNFR1. We also demonstrated that p21 and p27
differed in their localization and expression levels in the
experimental models represented by monolayers and
spheroids. While p27 was constitutively present, p21 was
induced on stimulation with TNF-α and the upregulation
in the spheroids was markedly higher compared to mon-
olayers.
p27 is expressed abundantly in human malignant gliomas
and is associated with better prognosis [39,40]. p27 is
normally a nuclear protein but cytoplasmic localization
has been demonstrated in breast and colon cancers and
correlates with poor survival in adenocarcinoma [23].
Relocalization of p27 in the cytoplasm is the result of
phosphorylation of p27 nuclear localization domain
induced by Akt kinase [36] and the presence of cytoplas-
mic p27 correlates with activated Akt in breast tumors
[41]. It is likely that such a correlation exists in gliomas
also as high basal levels and activated Akt were detected in
LN-18 cells (our unpublished data) and the cells were
highly positive for p27 with predominant cytoplasmic
localization. Interestingly, PI3K/Akt inhibitor had no
A-B. Effect of TNF-α on expression of pp53 and p65 in LN-229 cells (p53 positive)Figure 4
A-B. Effect of TNF-α on expression of pp53 and p65 
in LN-229 cells (p53 positive). A) LN-229 cells were 
exposed to TNF-α for 6 hr and stained with antibodies to 
phosphorylated Ser-20 p53 and p21. B) LN-229 cells were 
transfected with IκBα dominant negative construct and the 
expression of nuclear p65 was determined after exposure to 
TNF-α for 6 hr.
A-D. Effect of TNF-α on cell viability and expression of p21 and p27 in IκBα mutant LN-18 ce lsFigure 3
A-D. Effect of TNF-α on cell viability and expression 
of p21 and p27 in IκBα mutant LN-18 cells. (A) Wild 
and mutant IκBα LN-18 cells were treated with TNF-α (10 
ng/ml) for 12 hr and cell viability was assessed by MTT assay. 
The percent cell death was determined considering viability 
of control cells as 100%. (B) IκBα mutant LN-18 cells were 
treated with TNF-α (10 ng/ml) for different time points and 
cleavage of PARP (89 kD fragment) was determined by 
Western blotting. C) IκBα mutant LN-18 cells grown on 
coverslips were treated with TNF-α (10 ng/ml) for 3 hr and 
stained with p21 followed by secondary antibody labeled 
with Cy3 and DAPI was used for staining nucleus (Magnifica-
tion 63×). D) Expression of p21 and p27 determined by 
Western blotting in monolayers (M) and spheroids (S) 
derived from IκBα mutant LN-18 cells treated with TNF-α 
for 3 hr. The blots were stripped and reprobed with β-actin, 
which served as control for equal loading of proteins.Page 6 of 12
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that unlike the nuclear p27, cytoplasmic protein may not
be regulated via PI3K/Akt pathway. Our findings also rule
out the possibility of the involvement NF-κB in regulation
of p27 as there was no difference in the expression levels
between the parent and the IκBα mutant LN-18 cell lines,
which essentially differed in the NF-κB activity. It is
believed that p27 translocated to the cytoplasm initiates
its degradation and activates CDK2 and can enhance
import of cyclin D to the nucleus [41] resulting in the loss
of functionality of p27 in cytoplasm. On these lines, it is
reasonable to conjecture that the antiproliferative effect of
p27 may be functionally impaired in many cancers by
sequestration in cyclinD-CDK4/6 complexes and mislo-
calization in the cytoplasm away from the nuclear targets
[16,42]. LN-18 cells were highly positive for p27 and the
expression was significantly enhanced on spheroidogene-
sis. This finding is consistent with the reports that expres-
sion of p27 is regulated by contact inhibition and
increased level of p27 has been reported in tumor cell
lines maintained as spheroids as opposed to cell cultured
as monolayers [43]. Though p27 expression was
enhanced remarkably on stimulation with TNF-α, experi-
ments with p27-antisense oligonucleotides indicated that
p27 did not contribute to the inhibition of proliferation,
suggesting the loss of functionality of p27 as an inhibitor
of cell cycle. However, the role of cytoplasmic p27 during
spheroidogenesis and in response to TNF-α stimulation
remains unclear.
Elevated levels of p21 is reported in aggressive gliomas
and is used as a prognostic marker [44], surprisingly, p21
was not detectable in LN-18 cells. Evidence for the antia-
poptotic function of p21 has been provided in TNF-α
induced cytotoxicity in Ewing tumor and MCF-7 breast
carcinoma cell line [45], in differentiation induced apop-
tosis of monocytes [46] and CD95 mediated cell death in
human glioma cell lines [47]. In our study, p21 siRNA did
not induce cell death in TNF-α-stimulated LN-18 cells,
indicating that p21 did not have an antiapoptotic func-
tion.
Activation of NF-κB during TNF-α stimulation is believed
to one of the major factors contributing to resistance in
most tumors. It is speculated that constitutive activation
of NF-κB in glioblastoma multiforme (GBM) may be asso-
ciated with tumor resistance to TNF-α immunotherapy
[48]. To investigate the role of p21 in resistance to TNF-α
mediated cytotoxicity, we used a stable IκBα mutant LN-
18 cell line that was rendered sensitive to TNF-α induced
death by transfection with a double mutant construct
pcDNA3-IκBα in which both serines (32 and 36) at the
amino-terminal are replaced with alanine that are essen-
tial for phosphorylation of IκBα during NF-κB activation
[49]. In contrast to the parental LN-18 cells, which
showed upregulation of p21 in response to TNF-α treat-
A-B. TNF-α-induced p21 does not have antiapoptotic func-tionFigure 6
A-B. TNF-α-induced p21 does not have antiapoptotic 
function. (A) LN-18 cells were grown on coverslips and 
transfected with p21 siRNA oligonucleotides (100 nM) for 24 
hr. Control and transfected cells were treated with TNF-α 
(10 ng/ml) for 3 hr. Cells were stained with p21 antibody fol-
lowed by secondary antibody labeled with Cy3. DAPI was 
used for nuclear staining (blue fluorescence), merged images 
show nuclear localization of p21 (Magnification 63×). (B) 
Effect of TNF-α on viability in p21 siRNA transfected cells 
done by MTT assay. The graph represents mean +/- SD of 3 
experiments done in duplicates.
Effect of TNF-α on pp53 and p21 levels was studied in LN-229 cells transfected with IκBα dominant negative co struct by confocal la er scann ng microscopyFigure 5
Effect of TNF-α on pp53 and p21 levels was studied in LN-
229 cells transfected with IκBα dominant negative construct 
by confocal laser scanning microscopy. Treatment with pri-
mary antibodies was followed by incubation with appropriate 
secondary antibodies tagged to Cy3. DAPI was used for 
staining nucleus (Magnification 63×).Page 7 of 12
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suggesting an association between p21 expression and
NF-κB activity. This observation is in accordance with the
report demonstrating a correlation between p21 expres-
sion and NF-κB activity in Ewing tumor cells [45]. How-
ever, other studies demonstrate that p21 induction in
daunomycin treated breast and colon carcinoma cell lines
does not involve NF-κB though the p21 promoter harbors
p53 responsive elements and a functional NF-κB binding
site in these cells [50].
In light of a recent report by Schumm et al, demonstrating
the critical role of p52/p100 NF-κB subunit in p53-
dependent p21 regulation in U-2 0S cells [32], it was of
interest to investigate the role of p53 in TNF-α-induced
p21 in glioma cells. As LN-18 cells have mutant p53, we
used another human glioma cell line – LN-229, express-
ing wild type p53 protein. The tumor suppressor p53 is
post-translationally activated by different mechanisms
including phosphorylation on serine residues within the
C-terminus or N-terminal regions [51,52]. Phosphoryla-
tion of p53 at ser20 is an important event in modulation
of p53 stability and activity in response to UV and irradi-
ation [53] and is shown to activate p21 in response to
DNA damaging agents by enhancing transactivating func-
tion of p53 [54]. In this study, we found that TNF-α-
enhanced accumulation of pp53 was associated with
down regulation of p21 expression in LN-229 cells.
Upregulation of p53 accompanied by decreased p21
expression is a typical feature of inhibition of transcrip-
tion and has been demonstrated in LNCap cells treated
with flavopiridol [55]. Negative expression of p21 and
overexpression of p53 together is associated with aggres-
sive behavior in gastric tumors [56]. Furthermore, the data
from IκBα dominant negative construct transfected LN-
229 cells exposed to TNF-α suggested that p53 might not
be downstream of NF-κB and p21 could be regulated
independently by the p53. Our findings differ from the
study with MCF-7 cells reporting that p21 induced on
stimulation with TNF-α is not regulated by p53 but by NF-
κB [57]. It is note worthy that in LN-229 cells, dexameth-
osone does not induce p53 expression or alter camp-
tothecin induced p53 expression implying that while
regulation of p21 by p53 independent pathway in glioma
cells is believed to cell type specific [33], the response may
vary also depending on stimuli. Another important find-
ing of this study is that, p53 expression in LN-229 cells
was not influenced by the absence of functional IκBα sub-
stantiating the conclusion that p53 is not regulated by NF-
κB. This observation is differs from the report that IκBα
inhibits p53 by binding to it, resulting in cytoplasm p53
and hence prevents nuclear translocation [58].
A-B. Induction of p21 and p27 expression by TNF-α does not involve PI3K/Akt pathwayFigure 8
A-B. Induction of p21 and p27 expression by TNF-α 
does not involve PI3K/Akt pathway. (A) LN-18 cells 
grown on coverslips, were sensitized with LY294002 (50 µM) 
for 2 hr and treated with TNF-α (10 ng/ml) for 3 hr and the 
expression of p21 or (B) p27 was studied by confocal laser 
scanning microscopy. Cells were stained with p21/p27 anti-
bodies followed by secondary antibody labeled with Cy3. 
DAPI was used for nuclear staining (blue). Merged images 
depict nuclear localization for p21 and predominant cytoplas-
mic localization of p27. (Magnification 63×).
A-B. p21 but not p27 is involved in TNF-α induced inhibition of proliferationFigure 7
A-B. p21 but not p27 is involved in TNF-α induced 
inhibition of proliferation. (A) LN-18 cells were trans-
fected with p21 siRNA oligonucleotides (100 nM) or (B) p27 
antisense (As) oligonucleotides (200 nM) for 6 hr and cul-
tured as monolayers or spheroids for 18 hr. Cells were 
treated with TNF-α (10 ng/ml) for 24 hr, and tritiated thymi-
dine incorporation assay was done as described in Fig. 1. * p 
< 0.05 inhibition of proliferation with TNF-α in transfected 
versus untransfected cells. The data is representative of 
three experiments done in triplicates.Page 8 of 12
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[45]. To exert protective effect against damage induced by
apoptotic agents, it is essential that p21 is phosphorylated
and is localized in the cytoplasm [20]. We found that
TNF-α-induced p21 was restricted to the nucleus suggest-
ing that it might not function as an antiapoptotic protein.
Our conclusion that TNF-α-induced p21 was not phos-
phorylated and was restricted to nuclear localization is
based on our findings using two different antibodies to
examine the phosphorylation status of p21, an antibody
that was immunoreactive with nuclear as well as cytoplas-
mic p21 and a second antibody recognizing exclusively
phosphorylated p21 (details in materials and methods).
Though the molecular mechanisms in compartmentaliza-
tion of p21 are not clear, it is reported that Akt might reg-
ulate the subcellular changes [37]. Phosphotidylinositol
3-kinase (PI3K) and its downstream target, the Akt/PKB
serine threonine kinase [59] are activated on TNF-TNFR
binding. Akt activity is elevated in most GBM cells partic-
ularly those with mutant form of PTEN and is important
in glioma formation and progression [60]. Activation of
Akt is paralleled with increased p21 stability and corre-
lated with resistance to taxol-induced apoptosis in gliob-
lastoma cell lines [38]. High grade gliomas are known to
express high levels of Akt [52] and enhanced Akt activity
is demonstrated in spheroids from Ewing tumors [53]. We
observed increased levels and activity of Akt in spheroids
of LN-18 cells (our unpublished data). These findings and
our data depicting increased expression of TNF-α-induced
p21 in spheroids compared to monolayer cells prompted
us to examine the involvement of Akt in the regulation of
p21. We found that PI3K/Akt inhibitor-LY290042 did not
affect the expression of p21 suggesting that it was not reg-
ulated by this pathway. Experiments with p21 siRNA
reversed the inhibition of proliferation confirming its role
as a regulator of cell cycle progression. These results led us
to conclude that p21 functioned as an inhibitor of prolif-
eration but not as an antiapoptotic protein in TNF-α
mediated response in LN-18 cells. Furthermore, our stud-
ies with IκBα mutant LN-18 cells and pharmacological
inhibitor-LY290042 revealed that p21 expression was reg-
ulated by NF-κB and not Akt pathway.
In conclusion, this study demarcates the functions of
CDKIs-p21cip/waf1 and p27kip1 during TNF-α stimulated
responses in LN-18 glioma cells. p21 induced on stimula-
tion with TNF-α may be regulated by NF-κB or p53, prob-
ably depending on the status of p53. Our findings do not
support a role for p27 in regulation of proliferation or ren-
dering resistance in TNF-α induced cytotoxicity, which
could be attributed to its cytoplasmic localization. How-
ever questions concerning the relevance of enhanced cyto-
plasmic p27 expression during spheroidogenesis and in
response to TNF-α stimulation remain to be answered.
The findings in this study assume importance from the
point of TNF-α-TNFR1 interaction in the in vivo milieu in
gliomas wherein TNF-α is secreted by the tumor infiltrat-
ing macrophages and TNF receptors are abundantly
expressed by the tumor cells. The stimulation leads to acti-
vation of various pathways including NF-κB pathway
which contributes to chemoresistance. The resistance may
be further enhanced by induction of p21 by TNF-α in NF-
κB dependent manner leading to the arrest of cells in the
G1 phase. The regulation of p21 by p53 and NF-κB in wild
type p53 and mutant p53 tumors in response to TNF-α
deserves further in-depth studies Additionally, heightened
induction of p21 to TNF-α stimulation in MCS represent-
ing the cells in low proliferating phase underscore the
MCS as more realistic model for studying the molecular
mechanisms in resistance to chemotherapeutic agents in
solid tumors.
Methods
Cell cultures and generation of multicellular spheroids
The human glioma cell lines LN-18, LN-229 and U87MG
were procured from American Type Culture Collection
(ATCC, U.S.A). Cells were cultured in Dulbecco' s modi-
fied eagle's medium (DMEM) supplemented with 1.5 gm/
L sodium bicarbonate, 4 mM glutamine and 5%-10%
fetal bovine serum (Gibco, U.S.A) at 37°C in an atmos-
phere of 5% CO2/95% air. Multicellular spheroids were
generated by the liquid overlay technique as described
previously [61] with a slight modification. All experi-
ments were done using 24 hr cultures. Single cell suspen-
sions were prepared from spheroids by dissociation with
0.25% trypsin in PBS at 37°C for 30 min.
Cell viability assay
The effect of TNF-α on cell viability was assessed by MTT
(3-(4, 5-Dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazol-
lium bromide) assay. Cells were treated with TNF-α (1–
100 ng/ml) for 24 hr. During the last 4 hr of incubation,
10 µl of MTT (5 mg/ml) (Amersham Biosciences, U.S.A)
were added. The crystals were dissolved in 10%SDS-
0.01N HCl and absorbance was measured at 570 nm with
reference to 650 nm. The percent viability was calculated
considering controls as 100%. Cell death was also con-
firmed by trypan blue dye exclusion method.
Tritiated thymidine incorporation assay
Cell proliferation was measured by tritiated thymidine
incorporation assay. Cells were grown as monolayers or
spheroids in 96 well plates and treated with serial concen-
trations of TNF-α (1 to 100 ng/ml – Peprotech, U.S.A) for
24 hr, during the last 18 hr before termination of the
assay, 1 µCi tritiated thymidine (Specific activity 240
Gbq/mmole, from Board of Radiation and Isotope Tech-
nology-BRIT, India) were added to wells. Monolayer cells
were trypsinized in the same plate while spheroids werePage 9 of 12
(page number not for citation purposes)
Molecular Cancer 2007, 6:42 http://www.molecular-cancer.com/content/6/1/42transferred to fresh plate and harvested using cell har-
vester (Nunc, Denmark). The radio activity-Counts per
Minute (CPM) were measured using a liquid scintillation
counter (Packard, U.S.A). The percent inhibition was cal-
culated, considering incorporation in control (untreated)
cells as 100%.
Cell cycle analysis
Cells were plated at 2 × 106/100 mm dish in duplicates
and treated with TNF-α (10 ng/ml) up to 72 hr. Cells were
harvested at 24 hr interval post-treatment, stained with
propidium iodide (50 µg/ml) and DNA content was
determined on the FL-2A channel with flowcytometer
equipped with 488 nm argon laser (FACS Vantage – BD
Sciences, U.S.A). The data was analyzed using Modfit soft-
ware to determine population in different phases of cell
cycle.
Western blotting
Cells were lysed in RIPA buffer (50 mM Tris-HCl, pH 7.4,
150 mM NaCl, 1% TritonX-100, 1% NP-40, 1% Sodium
deoxycholate, 0.1% Sodium dodecyl sulphate, 2 mM Phe-
nylmethylsulfonylfluoride, 50 mM Sodium fluoride, 5
mM iodoacetamide, 2 mM β-glycero-phosphate, 1 mM
benzamidine, 1 mM sodium orthovanadate) and protease
inhibitor cocktail (Roche, Germany). Protein samples
were separated by SDS-PAGE (10–15%) and electro-trans-
ferred onto PVDF membrane (Amersham BioSciences,
U.S.A). The expression of proteins was analyzed using
antibodies to p21 and p27 (Cell Signaling and Santacruz
Biotechnology, U.S.A), TNFR1 (R&D Systems, U.S.A). The
blots were incubated with appropriate secondary antibod-
ies conjugated to horse radish peroxidase (Biorad, U.S.A),
and developed using ECL PLUS kit (Amersham Bio-
sciences, U.S.A). The protein levels were normalized by
reprobing the blots with antibody to β-actin (ICN, U.S.A).
Confocal laser scanning microscopy
Cells grown for 24 hr on cover slips were treated with
TNF-α (10 ng/ml) for different time points. Cells were
washed twice with PBS, fixed with 3.7% paraformalde-
hyde for 10 min at RT. Cells were permeabilized with
0.2% Triton-X 100 for 5 min and blocked with PBS con-
taining 1% BSA and 10% goat serum for 30 min. Cells
were incubated with appropriately diluted antibodies to
pp53, p65, and p27 (SantaCruz Biotechnology, U.S.A)
p21, pp21(Cell Signaling Technology, U.S.A) overnight,
washed and incubated with corresponding secondary
antibodies labeled with Cy-3 for I hr. Cells were washed
with PBS, stained with DAPI (0.5 µg/ml) and mounted in
mounting media (Oncogene, U.S.A) and viewed under
Confocal microscope (Zeiss LSM 510, Germany)
equipped with argon laser and helium lasers. The controls
comprised of cells processed with isocontrol antibody or
without primary antibody. For assessing the role of PI3K/
Akt pathway in the regulation of p27 and p21, cells were
incubated for 2 hr with LY290042 (Calbiochem, U.S.A), a
pharmacological inhibitor of PI3K/Akt prior to TNF-α
treatment.
Cell transfections and generation of IκBα mutant stable 
LN-18 cell line
IκBα mutant stable cell line was generated using a double
mutant construct in which both serines (32 and 36) at the
amino-terminal of IκBα, are mutated to alanine. DNA was
mixed with 10 µl lipofectamine 2000 (Invitrogen, U.S.A)
in 500 µl of serum free medium for 30 min and layered
over the LN-18 cells grown at 50% confluence and after 6
hr the medium was changed. After incubation for 24 hr,
the cells were grown in selection medium (G418, 600 µg/
ml) and clones were picked and plated into 96 well plates.
Single cell colonies were grown in G418 (400 µg/ml).
Transfections done with empty vectors comprised as con-
trols. The mutant status in the cell line was confirmed by
analyzing the response to TNF-α by IκBα degradation and
p65 nuclear localization. Transient transfections were
done with IκBα dominant negative construct in LN-229
cells.
Antisense oligonucleotide transfection
LN-18 cells were transfected with 200 nM of p27 phos-
phorothioate labeled antisense oligonucleotides synthe-
sized by Life technologies, U.S.A. The sequences were as
follows – p27 antisense-5'-gacactctcacgtttgacat-3', scram-
bled-5'-ttgccgctgctaagttcg-3', using oligofectamine (Invit-
rogen, U.S.A) in serum free medium. After 6 hr, the
medium was supplemented with serum, cultured for 24
hr and treated with TNF-α (10 ng/ml). Western blot anal-
ysis for confirming p27 expression and tritiated thymi-
dine assays were performed as described above.
Transfection with p21 siRNA
Cells were cultured for 24 hr and transfected with p21
siRNA oligonucleotides (50 nM) according to the manu-
facturer's instructions (Cell Signaling Technology, U.S.A).
After 24 hr, medium was replaced and cells were treated
with TNF-α (10 ng/ml) for 3 hr and processed for p21
staining, proliferation and viability assays as described
above.
Statistical analysis
Statistical analysis was performed using one-way analysis
of variance (ANOVA) followed by students t-test or
Fisher's exact test. A p-value < 0.05 was considered to be
statistically significant.
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